Engineering the Artificial Pancreas: Closing the Loop on Diabetes

Eiliyah Annam
Jan 15
5 min read

Type 1 diabetes (T1D) is an autoimmune disease where the body's immune system mistakenly attacks and destroys the islet cells (insulin producing cells) of the pancreas. This results in the body producing very little to no insulin, the horomone necessary for cells to absorb glucose from the bloodstream for energy. Without insulin, glucose builds up in the blood, which, if not properly regulated, can lead to serious health problems and life-threatening complications. However, regulating insulin is difficult due to the constant changes in glucose levels influenced by diet, physical activity, and stress.

T1D patients must constantly monitor their blood glucose levels, meticulously count carbohydrates for every meal, and administer insulin through multiple daily injections or a manual pump. Without proper management, patients face both immediate and long-term health risks. These immediate risks include hypoglycemia and hyperglycemia. Hypoglycemia occurs when blood sugar becomes dangerously low which can cause confusion, loss of consciousness, and is especially risky during sleep. Hyperglycemia is when blood sugar becomes chronically high which can damage major organs and blood vessels, leading to long-term complications. The long-term complications include retinopathy (eye damage), nephropathy (kidney damage), neuropathy (nerve damage), and an increased risk of heart disease and stroke. The relentless nature of T1D management imposes a significant emotional and cognitive load. This can lead to anxiety, depression, and "diabetes burnout", where patients feel overwhelmed by the constant decision-making and vigilance that is required.

One way to combat this issue is the artificial pancreas, which is a system that mimics the functions of a healthy pancreas and uses closed-loop insulin delivery to automate diabetes care. By continously monitoring glucose and automatically adjusting insulin delivery, these systems aim to significantly reduce the burden of T1D managment and improve patients' quality of life.

The closed-loop system present in the artifical pancreas is an automated insulin delivery system that senses blood glucose levels and adjusts insulin delivery to mimic the function of a healthy pancreas. Unlike earlier open-loop systems, which require manual input for insulin calculations, closed-loop systems automate this process. The basic components for closed-loop systems are a Continuous Glucose Monitor (CGM), a inlsulin pump, and a control algorithm. A CGM is a tiny sensor that is worn under the skin which measures the glucose levels in the interstitial fluid every few minutes and wirelessly sends this data. An insulin pump is a device that delivers rapid-acting insulin through a catheter, either via tubing or a tubeless patch. Additionally, the control algorithm is the "brain" of the system and receives data from the CGM and uses predictive modeling and complex calculations to determine the precise amount of insulin needed, and when to deliver it.

These systems offer life-changing benefits for people with T1D by reducing the mental burden of disease management through improved glucose control. Clinical trials have shown that these systems improve A1C levels (a measure of average blood glucose), significantly increases the percentage of time patients spend in their target glucose range, and reduces the risk of complications. It was also observed that better glucose control directly translates to a lower risk of both short-term hypoglycemic events and long-term complications caused by chronic hyperglycemia.

Automating insulin delivery and continuous monitoring gives patients a degree of freedom and flexibility, allowing them to worry less about their condition during daily activities and especially overnight. Patient testimonials frequently cite improved sleep quality and reduced anxiety due to the system's ability to manage glucose levels overnight.

In developing and refining the technologies that make the artifical pancreas possible, biomedical engineers have played a critical role. This role includes designing and improving sensors. Engineers continually work to increase the accuracy, lifespand, and biocompatibility of CGM sensors. Recent innovations, for example, have improved performance and reduced sensor dropouts. Creating smart insulin pumps (miniaturization, responsiveness), miniaturization of pumps, improved wireless communication, and enhanced pump durability have all been engineering achievements. Additionally, they have developed sophisticated algorithms that use predictive artificial intelligence and adaptive feedback loops to learn a patient's unique insulin needs and respond to trends in glucose levels, not just current readings.

Some of the recent breakthroughs consist of the U.S. Food and Drug Administration (FDA) approving several hybrid closed-loop systems, which automate basal insulin delivery and make some corrections while still requiring user input for meals. Notable examples include the Tandem Control-IQ, Medtronic MiniMed 780G, and Insulet Omnipod 5.

With the various benefits with the artificial pancreas, comes multiple barriers. For example, the high cost of devices, sensors, and supplies, along with inconsistent insurance coverage, presents a significant challenge to widespread adoption. Furthermore, there is an inherent lag between when a CGM measures glucose in the interstitial fluid and when insulin delivered subcutaneously takes effect. This can make it difficult for the system to respond to rapid changes, like those occuring after a meal. Device calibrations, sensor accuracy issues, and dependence on external devices like smartphones or transmitters can also create technical problems. In addition, moving from hybrid to fully automated, or "hands-off", systems presents additional challenges for regulatory bodies like the FDA, as it requires rigorous testing to prove safety and efficacy without user input.

The field of artificial pancreas technology continues to evolve rapidly. The ultimate goal is a fully automated system that requires no user input for meals or exercise. The iLet Bionic Pancreas from Beta Bionics is an early example of this technology. Researchers are developing systems that would use both insulin to lower blood glucose and glucagon to raise it. This would more accurately replicate the function of a healthy pancreas, allowing for even tighter glucose control and greater protection against hypoglycemia. Researchers hope that future systems will be seamlessly integrated with wearable technology and use increasingly powerful AI-driven personalization to adapt to each individual's unique needs and patterns.

The development of the artificial pancreas represents a monumental leap forward in diabetes care, leveraging biomedical engineering to transform the lives of people with Type 1 diabetes. While challenges remain, the progress made in sensor technology, pump design, and control algorithms has profoundly improved glucose control, reduced complications, and eased the daily burden on patients. As biomedical innovation continues to drive the field, moving toward fully autonomous and personalized systems, the vision of a life free from the constant calculations and worries of diabetes grows ever closer. With every algorithm refined and every device improved, we are one step closer to giving people with diabetes the freedom that they deserve.

Sources

Assessed and Endorsed by the MedReport Medical Review Board